Multivariable OS after HLH assessment for each mutation stratified by specific T-cell malignancy, adjusting for age and sex
| Characteristics . | Mutations . | n . | Event, n . | HR . | 95% CI . | P value . |
|---|---|---|---|---|---|---|
| FAS mutation | Absent | 187 | 98 | Ref. | Ref. | |
| Present | 19 | 11 | 1.66 | 0.87-3.16 | .12 | |
| HLA-A mutation | Absent | 195 | 100 | Ref. | Ref. | |
| Present | 11 | 9 | 1.82 | 0.88-3.78 | .11 | |
| CDKN1B mutation | Absent | 204 | 107 | Ref. | Ref. | |
| Present | 2 | 2 | 16.2 | 3.11-84.4 | <.001 | |
| CASP8 mutation | Absent | 203 | 106 | Ref. | Ref. | |
| Present | 3 | 3 | 5.44 | 1.62-18.3 | .006 | |
| TP53 mutation | Absent | 173 | 87 | Ref. | Ref. | |
| Present | 33 | 22 | 1.7 | 1.03-2.80 | .037 | |
| TET2 mutation | Absent | 139 | 75 | Ref. | Ref. | |
| Present | 67 | 34 | 1.10 | 0.63-1.91 | .7 | |
| STAT3 mutation | Absent | 181 | 99 | Ref. | Ref. | |
| Present | 25 | 10 | 0.61 | 0.32-1.19 | .15 | |
| STAT5B mutation | Absent | 191 | 98 | Ref. | Ref. | |
| Present | 15 | 11 | 1.29 | 0.66-2.51 | .5 | |
| ROHA mutation | Absent | 172 | 92 | Ref. | Ref. | |
| Present | 34 | 17 | 1.27 | 0.64-2.54 | .5 | |
| RARA mutation | Absent | 200 | 104 | Ref. | Ref. | |
| Present | 6 | 5 | 1.69 | 0.64-4.43 | .3 | |
| TNFA1P3 mutation | Absent | 198 | 105 | Ref. | Ref. | |
| Present | 8 | 4 | 1.78 | 1.63-5.04 | .3 | |
| KMT2D mutation | Absent | 191 | 99 | Ref. | Ref. | |
| Present | 15 | 10 | 1.37 | 0.70-2.09 | .4 | |
| DNMT3A mutation | Absent | 177 | 93 | Ref. | Ref. | |
| Present | 29 | 16 | 1.41 | 0.79-2.52 | .2 | |
| Any mutations involving FAS, CASP8, and TNFA1P3 | Absent | 179 | 93 | Ref. | Ref. | |
| Present | 27 | 16 | 1.91 | 1.10-3.34 | .022 | |
| No. of mutations involving FAS, CASP8, and TNFA1P3 | 0 | 179 | 93 | Ref. | Ref. | |
| 1 | 24 | 14 | 1.80 | 1.00-3.24 | .048 | |
| 2 | 3 | 2 | 3.45 | 0.79-15.0 | .10 |
| Characteristics . | Mutations . | n . | Event, n . | HR . | 95% CI . | P value . |
|---|---|---|---|---|---|---|
| FAS mutation | Absent | 187 | 98 | Ref. | Ref. | |
| Present | 19 | 11 | 1.66 | 0.87-3.16 | .12 | |
| HLA-A mutation | Absent | 195 | 100 | Ref. | Ref. | |
| Present | 11 | 9 | 1.82 | 0.88-3.78 | .11 | |
| CDKN1B mutation | Absent | 204 | 107 | Ref. | Ref. | |
| Present | 2 | 2 | 16.2 | 3.11-84.4 | <.001 | |
| CASP8 mutation | Absent | 203 | 106 | Ref. | Ref. | |
| Present | 3 | 3 | 5.44 | 1.62-18.3 | .006 | |
| TP53 mutation | Absent | 173 | 87 | Ref. | Ref. | |
| Present | 33 | 22 | 1.7 | 1.03-2.80 | .037 | |
| TET2 mutation | Absent | 139 | 75 | Ref. | Ref. | |
| Present | 67 | 34 | 1.10 | 0.63-1.91 | .7 | |
| STAT3 mutation | Absent | 181 | 99 | Ref. | Ref. | |
| Present | 25 | 10 | 0.61 | 0.32-1.19 | .15 | |
| STAT5B mutation | Absent | 191 | 98 | Ref. | Ref. | |
| Present | 15 | 11 | 1.29 | 0.66-2.51 | .5 | |
| ROHA mutation | Absent | 172 | 92 | Ref. | Ref. | |
| Present | 34 | 17 | 1.27 | 0.64-2.54 | .5 | |
| RARA mutation | Absent | 200 | 104 | Ref. | Ref. | |
| Present | 6 | 5 | 1.69 | 0.64-4.43 | .3 | |
| TNFA1P3 mutation | Absent | 198 | 105 | Ref. | Ref. | |
| Present | 8 | 4 | 1.78 | 1.63-5.04 | .3 | |
| KMT2D mutation | Absent | 191 | 99 | Ref. | Ref. | |
| Present | 15 | 10 | 1.37 | 0.70-2.09 | .4 | |
| DNMT3A mutation | Absent | 177 | 93 | Ref. | Ref. | |
| Present | 29 | 16 | 1.41 | 0.79-2.52 | .2 | |
| Any mutations involving FAS, CASP8, and TNFA1P3 | Absent | 179 | 93 | Ref. | Ref. | |
| Present | 27 | 16 | 1.91 | 1.10-3.34 | .022 | |
| No. of mutations involving FAS, CASP8, and TNFA1P3 | 0 | 179 | 93 | Ref. | Ref. | |
| 1 | 24 | 14 | 1.80 | 1.00-3.24 | .048 | |
| 2 | 3 | 2 | 3.45 | 0.79-15.0 | .10 |